Results from a proof-of-concept clinical trial of the drug MP4OX in severely injured trauma patients with hemorrhagic shock showed that MP4OX, when given in addition to standard of care, was effective at decreasing lactate levels in treated patients. MP4OX is an oxygen therapeutic agent that is designed to provide rapid oxygen delivery to tissues with a depleted blood supply, made by Sangart Inc. of San Diego, California.
During hemorrhagic shock, inadequate fluid flow in critical organs can lead to insufficient oxygenation of tissues, which can be detected by an increase in lactic acid levels. The study data show greater immediate and sustained decreases of lactic acid in patients treated with MP4OX compared to patients in the control group. The study also found that a greater proportion of patients treated with MP4OX were able to attain normal lactate levels as early as four hours after treatment.
The data had other positive benefits, including fewer average number of days patients spent in hospital. In patients treated with MP4OX, the median hospital stay was half that of the control group. Rates of serious adverse events were about the same and similar in nature in both the MP4OX-treated and control groups.
The clinical trial was a multi-center, randomized, double-blind, controlled study with 51 patients who suffered trauma-induced severe hemorrhagic shock across 11 clinical sites in the United Kingdom, Germany, France and South Africa.
Photo: Michael Gil/Flickr
RSS - Posts
You must be logged in to post a comment.